CFM
CGTX icon

Catalyst Funds Management’s Cognition Therapeutics CGTX Stock Holding History

Catalyst Funds Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,800
Closed -$40.1K – 697
2026
Q1 		$40.1K Buy
+52,800
New +$61.5K 0.01% 553

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Catalyst Funds Management's CGTX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 52,800 shares — an estimated $40.1K sold.

Catalyst Funds Management first reported a position in CGTX in Q1 2026 and held it in 1 quarter. The position peaked at $40.1K in Q1 2026. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 52,800 Cognition Therapeutics shares in Q2 2026, an estimated $40.1K.
  • Catalyst Funds Management first reported a position in Cognition Therapeutics in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Cognition Therapeutics position peaked at $40.1K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.